EPCORITAMAB PHARMACOKINETICS IN PEDIATRIC PATIENTS WITH AGGRESSIVE MATURE B- CELL NEOPLASMS (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 172; Pres time: Sep 17, 2026; Location: Exhibition Area; "Background and Aims: Epcoritamab is a bispecific CD20-directed CD3-T-cell engager approved as monotherapy for treating adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), R/R follicular lymphoma (FL) after ≥2 lines of systemic therapy or in combination with lenalidomide and rituximab for R/R FL. Epcoritamab pharmacokinetics are consistent between pediatric patients in EPCORE®- Peds-1 and adults. Epcoritamab plasma exposures in pediatric patients receiving weight-based dosing are predicted to be within the exposure ranges in adults for the 48mg full dose."
Clinical • PK/PD data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Pediatrics • CD20
|
|
Mohamed Nounou1; Heiko Babel2; Melanie Rinas2; Behnam Noorani1; Tommy Li3; Xu Steven Xu3; Benjamin Engelhardt2; Toshihiko Oki4; Mohamed-Eslam Mohamed1
|